Description: Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.
Home Page: www.medexus.com
10 King Street East
Toronto,
ON
M5C 1C3
Canada
Phone:
877 422 5242
Officers
| Name | Title |
|---|---|
| Mr. Kenneth d'Entremont | CEO & Director |
| Mr. Richard Labelle | Chief Operating Officer |
| Mr. Ian C. Wildgoose Brown | General Counsel & Corporate Secretary |
| Mr. Brendon Buschman | Chief Financial Officer |
| Ms. Tina Byers CFA | Executive of Investor Relations |
| Mr. Bill Poncy | Senior Vice President of Commercial Operations - United States |
| Mr. Brian Peters | Vice President of Sales & Marketing - United States |
Exchange: OTCQX
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 16.6113 |
|---|---|
| Trailing PE: | 23.8889 |
| Price-to-Book MRQ: | 1.6189 |
| Price-to-Sales TTM: | 0.506 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 82 |